Form 4: CYTK Officer Sells Shares Under 10b5-1 Plan

Cytokinetics EVP Andrew Callos sold 1,709 shares of common stock for $61.03 per share under a pre-arranged trading plan.

Summary

• Andrew Callos, Executive Vice President and Chief Commercial Officer of Cytokinetics Inc. (CYTK), reported a sale of company common stock.
• On March 16, 2026, Mr. Callos disposed of 1,709 shares of CYTK common stock.
• The shares were sold at a price of $61.03 per share.
• This transaction was executed pursuant to a Rule 10b5-1 trading plan, indicating it was pre-scheduled.
• Following this transaction, Mr. Callos beneficially owns 46,149 shares of Cytokinetics common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While an insider sale could be seen negatively, its execution under a 10b5-1 plan suggests a pre-planned, routine transaction rather than a reaction to new information.

Positives

• The transaction was executed under a Rule 10b5-1 plan, which suggests a pre-scheduled sale rather than a reaction to recent non-public information, mitigating potential negative interpretations.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived as a lack of confidence in the company's near-term prospects, though the 10b5-1 plan mitigates this interpretation.

Industry Context

StockSavvy.ai notes that routine insider sales, particularly those executed under Rule 10b5-1 plans, are common for executives managing personal finances or diversifying portfolios and typically do not signal significant shifts in industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: A minor increase in the public float and a slight signal of insider activity, though mitigated by the 10b5-1 plan.

Key Dates

Keywords

Cytokinetics, CYTK, Andrew Callos, insider trading, Form 4, stock sale, 10b5-1 plan, executive compensation, common stock